[1]
|
Rohrer, J.D., Lashley, T., Schott, J.M., et al. (2011) Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain, 134, 2565-2581. doi:10.1093/brain/awr198
|
[2]
|
Rascovsky, K., Hodges, J.R., Knopman, D., et al. (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 134, 2456-2477. doi:10.1093/brain/awr179
|
[3]
|
Lopez, O.L., Becker, J.T., Klunk, W., et al. (2000) Research evaluation and diagnosis of probable Alzheimer’s disease over the last two decades: I. Neurology, 55, 1854- 1862. doi:10.1212/WNL.55.12.1854
|
[4]
|
Cummings, J.L. (2000) Cognitive and behavioral heterogeneity in Alzheimer’s disease: Seeking the neurobiological basis. Neurobiology of Aging, 21, 845-861.
doi:10.1016/S0197-4580(00)00183-4
|
[5]
|
Kertesz, A., McMonagle, P., Blair, M., et al. (2005) The evolution and pathology of frontotemporal dementia. Brain, 128, 1996-2005. doi:10.1093/brain/awh598
|
[6]
|
Forman, M.S., Farmer, J., Johnson, J.K., et al. (2006) Frontotemporal dementia: Clinicopathological correlations. Annals of Neurology, 59, 952-962.
doi:10.1002/ana.20873
|
[7]
|
Visser, P.J., Verhey, F., Knol, D.L., et al. (2009) Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. The Lancet Neurology, 8, 619-627.
doi:10.1016/S1474-4422(09)70139-5
|
[8]
|
Mattsson, N., Zetterberg, H., Hansson, O., et al. (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. The Journal of the American Medical Association, 302, 385-393.
doi:10.1001/jama.2009.1064
|
[9]
|
Tapiola, T., Alafuzoff, I., Herukka, S.-K., et al. (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Archives of Neurology, 66, 382-389.
doi:10.1001/archneurol.2008.596
|
[10]
|
Premi, E., Garibotto, V., Alberici, A., et al. (2012) Nature versus nurture in frontotemporal lobar degeneration: the interaction of genetic background and education on brain damage. Dementia and Geriatric Cognitive Disorders, 33, 372-378. doi:10.1159/000339366
|
[11]
|
Bian, H., Van Swieten, J.C., Leight, S., et al. (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology, 70, 1827-1835.
|
[12]
|
Seelaar, H., Rohrer, J.D., Pijnenburg, Y.A.L., et al. (2011) Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review. Journal of Neurology, Neurosurgery & Psychiatry, 82, 476-486.
doi:10.1136/jnnp.2010.212225
|
[13]
|
Davies, R.R., Hodges, J.R., Kril, J.J., et al. (2005) The pathological basis of semantic dementia. Brain, 128, 1984- 1995. doi:10.1093/brain/awh582
|
[14]
|
Grossman, M. (2010) Primary progressive aphasia: Clinicopathological correlations. Nature Reviews. Neurology, 6, 88-97. doi:10.1038/nrneurol.2009.216
|
[15]
|
Mesulam, M., Wicklund, A., Johnson, N., et al. (2008) Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Annals of Neurology, 63, 709- 719. doi:10.1002/ana.21388
|
[16]
|
Deramecourt, V., Lebert, F., Debachy, B., et al. (2010) Prediction of pathology in primary progressive language and speech disorders. Neurology, 74, 42-49.
doi:10.1212/WNL.0b013e3181c7198e
|
[17]
|
Cairns, N.J., Bigio, E.H., Mackenzie, I.R., et al. (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathologica, 114, 5-22.
doi:10.1007/s00401-007-0237-2
|
[18]
|
Sampathu, D.M., Neumann, M., Kwong, L.K., et al. (2006) Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. The American Journal of Pathology, 169, 1343-1352. doi:10.2353/ajpath.2006.060438
|
[19]
|
Verwey, N.A., Kester, M.I., van der Flier, W.M., et al. (2010) Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. Journal of Alzheimer’s Disease, 20, 445-452.
|
[20]
|
Urakami, K., Wada, K., Arai, H., et al. (2001) Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. Journal of the Neurological Sciences, 183, 95-98. doi:10.1016/S0022-510X(00)00480-9
|
[21]
|
Paraskevas, G.P. (2005) The diagnostic value of cerebrospinal fluid tau protein in sementing and nondementing neuropsychiatric disorders. Journal of Geriatric Psychiatry and Neurology, 18, 163-173.
doi:10.1177/0891988705277549
|
[22]
|
Arai, H., Morikawa, Y., Higuchi, M., et al. (1997) Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochemical and Biophysical Research Communications, 236, 262-264.
doi:10.1006/bbrc.1997.6908
|
[23]
|
Noguchi, M., Yoshita, M., Matsumoto, Y., et al. (2005) Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. Journal of the Neurological Sciences, 237, 61-65. doi:10.1016/j.jns.2005.05.015
|
[24]
|
Sha, S., Hou, C., Viskontas, I.V., et al. (2006) Are frontotemporal lobar degeneration, progressive supranuclear palsy and corticobasal degeneration distinct diseases? Nature Clinical Practice. Neurology, 2, 658-665.
doi:10.1038/ncpneuro0357
|
[25]
|
Chand, P., Grafman, J., Dickson, D., et al. (2006) Alzheimer’s disease presenting as corticobasal syndrome. Movement Disorders, 21, 2018-2022.
doi:10.1002/mds.21055
|
[26]
|
Boeve, B.F., Lang, A.E. and Litvan, I. (2003) Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Annals of Neurology, 54, S15-S19. doi:10.1002/ana.10570
|
[27]
|
Lang, A.E. (2003) Corticobasal degeneration: Selected developments. Movement Disorders, 18, S51-S56.
doi:10.1002/mds.10563
|
[28]
|
Dickson, D.W. (2012) Parkinson’s disease and parkinsonism: Neuropathology. Cold Spring Harbor Perspectives in Medicine, 2, a009258.
|
[29]
|
Borroni, B., Malinverno, M., Gardoni,F., et al. (2008) Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology, 71, 1796-1803.
doi:10.1212/01.wnl.0000335941.68602.39
|
[30]
|
Dubois, B., Feldman, H.H., Jacova, C., et al. (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. The Lancet Neurology, 6, 734-746. doi:10.1016/S1474-4422(07)70178-3
|
[31]
|
Hu, W.T., Rippon, G.W., Boeve, B.F., et al. (2009) Alzheimer’s disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders, 24, 1375- 1379. doi:10.1002/mds.22574
|
[32]
|
Grossman, M., Libon, D.J., Forman, M.S., et al. (2007) Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Archives of Neurology, 64, 1601-1609. doi:10.1001/archneur.64.11.1601
|
[33]
|
Jellinger, K.A. and Attems, J. (2010) Prevalence of dementia disorders in the oldest-old: An autopsy study. Acta Neuropathology, 119, 421-433.
doi:10.1007/s00401-010-0654-5
|
[34]
|
Cohen, A.D., Rabinovici, G.D., Mathis, C.A., et al. (2012) Using pittsburgh compound B for in vivo PET imaging of fibrillar amyloid-beta. Advances in Pharmacology, 64, 27-81. doi:10.1016/B978-0-12-394816-8.00002-7
|